All Names: Acalabrutinib,Calquence,Acalanib
Indications:1. Mantle Cell Lymphoma; 2. Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Manufacturer:Lucius,India
Customs Clearance Procedure:If the customs requires the package for customs clearance, please pay the customs clearance fee according to the content of EMS SMS and customs regulations.
INDICATIONS AND USAGE(适应症)
Mantle Cell Lymphoma
CALQUENCE is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
DOSAGE(服用剂量)
CALQUENCE as Monotherapy
For patients with MCL, CLL, or SLL, the recommended dose of CALQUENCE is 100 mg taken orally approximately every 12 hours until disease progression or unacceptable toxicity.
CALQUENCE in Combination with Obinutuzumab
For patients with previously untreated CLL or SLL, the recommended dose of CALQUENCE is 100 mg taken orally approximately every 12 hours until disease progression or unacceptable toxicity. Start CALQUENCE at Cycle 1 (each cycle is 28 days). Start obinutuzumab at Cycle 2 for a total of 6 cycles and refer to the obinutuzumab prescribing information for recommended dosing. Administer CALQUENCE prior to obinutuzumab when given on the same day.
Advise patients to swallow capsule whole with water. Advise patients not to open, break or chew the capsules. CALQUENCE may be taken with or without food. If a dose of CALQUENCE is missed by more than 3 hours, it should be skipped and the next dose should be taken at its regularly scheduled time. Extra capsules of CALQUENCE should not be taken to make up for a missed dose.
ADVERSE REACTIONS(不良反应)
Serious and Opportunistic Infections
Hemorrhage
Cytopenias
Second Primary Malignancies
Atrial Fibrillation and Flutter
For full information, please refer to:
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/dd4835ef-e1bc-4997-a399-1ffa2556fbfe/spl-doc?hl=Acalabrutinib
Luciacalabruinformation